Detection of *Clostridioides difficile* toxin B gene: benefits of identifying gastrointestinal pathogens by mPCR assay in the diagnosis of diarrhea in pediatric patients

Jung-Hyun Byun¹, Dongeun Yong² and Heejung Kim³*

**Abstract**

**Background:** In the pediatric population, severe *Clostridioides difficile* infection (CDI) sometimes occurs, but most cases are asymptomatic. The asymptomatic carriage rate in pediatric populations is reportedly higher than in the adult population. It is difficult to diagnose CDI, even if *C. difficile* is detected in children with diarrhea. This study aimed to evaluate the positivity rate of toxigenic *C. difficile* in the pediatric population with diarrhea.

**Methods:** We collected and retrospectively analyzed gastrointestinal pathogen multiplex PCR results of 960 patients to estimate the positivity rate of toxigenic *C. difficile* in pediatric populations aged between 0 and 18 years.

**Results:** The overall rate of *C. difficile* toxin B positivity was 10.1% in the stool samples. The positivity rate peaked in 1-year-old infants (29/153, 19.0%) and continually decreased thereafter. The positivity rate we observed was lower than the rates described in the literature. Remarkably, no *C. difficile* was detected in neonates. Antibiotic usage was inversely related to the positivity rate, especially in infants < 2 years of age. The odds ratio of antibiotics was 0.44 (95% confidence interval (CI) 0.28–0.68; *P* < 0.001). The presence of concomitant gastrointestinal pathogens was not associated with toxigenic *C. difficile* positivity.

**Conclusions:** Even though toxigenic *C. difficile* infection is neither an important nor a common cause of pediatric diarrhea, children can spread it to adults at risk of developing CDI. The pediatric population can act as hidden reservoirs for pathogenic strains in the community.

**Keywords:** *Clostridioides difficile*, Intestinal colonization, CDI, Toxin, Bacterial diarrhea

---

**Background**

*Clostridioides difficile*, formerly known as *Clostridium difficile*, is a spore-forming, obligate anaerobic, gram-positive bacillus acquired either from the environment or through the fecal-oral route [1]. It is known to cause a wide range of symptoms, from mild diarrhea to severe life-threatening complications such as toxic megacolon [2]. The major virulence factors of *C. difficile* are large clostridial toxins, toxin A and toxin B, which are encoded by *tcdA* and *tcdB* [3]. *C. difficile* infection (CDI) mainly occurs in healthcare-associated cases and adults. However, over the last decade, CDI has emerged as an important community-associated infection both in adults and children [4]. Approximately 4–5% of non-hospitalized healthy adults carry the pathogen in their intestinal flora [5], and varying positive rates of up to 70% have been reported in healthy newborns [6].

*Correspondence: hjkim12@yuhs.ac*

1 Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Severance Hospital, Yonsei University School of Medicine, Yongin, Gyeonggi-do, South Korea

Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
children, the carrying capacity decreases with age, reaching adult levels of approximately 5% by the age of 2 [7]. According to the guidelines for pediatric consideration, because of the high prevalence of asymptomatic carriage of toxigenic *C. difficile*, testing for CDI should not be routinely performed in children under 12 months of age with diarrhea [1, 8]. If they have rare and severe symptoms of pseudomembranous colitis, toxic megacolon, or clinically significant diarrhea, *C. difficile* testing should be performed. In children aged between 1 and 3 years, a diagnostic workup for other diarrheal causes should be performed first, while *C. difficile* testing can be considered at later stages. Due to the unclear role of *C. difficile* in children with diarrhea, there are few reports on the positivity of toxigenic *C. difficile* in the pediatric population. Therefore, this study focuses on multiplex PCR (mPCR), which is increasingly being applied to detect gastrointestinal pathogens and provides additional information on the *C. difficile* toxin B gene (*tcdB*) in pediatric patients. In this study, we estimated the positivity rate of *C. difficile tcdB* and interpreted the results through electronic medical record review.

**Methods**

We reviewed 960 non-duplicated stool mPCR (Seeplex Diarrhea-B1/2 and V ACE Detection, Seegen, Korea) results obtained from pediatric patients up to the age of 18 [9] collected over 39 months (October 2014–December 2017) and submitted to a tertiary referral hospital in Seoul. The mPCR included *C. difficile tcdB* and 13 other diarrheal-causing pathogens (*Salmonella* spp., *Shigella* spp., *Vibrio* spp., *Campylobacter* spp., *Escherichia coli* O157:H7, *Clostridium perfringens*, *Yersinia enterocolitica*, *Aeromonas* spp., Verocytotoxin-producing *E. coli*, rotavirus group A, norovirus, astrovirus, and enteric adenovirus). The electronic medical records of the patients were reviewed to acquire information regarding age, length of hospital stay, underlying diseases (malignant neoplasm, hematology/immunology, endocrinology, cardiovascular, respiratory, digestive, inflammatory bowel diseases, and genitourinary disorder), previous history of antibiotics, and clinical diagnosis of *C. difficile* enterocolitis during the entire period of hospitalization with or without metronidazole or oral vancomycin treatment.

Unpaired *t*-test or Mann-Whitney U test was used for continuous data. Pearson's chi-squared test or Fisher's exact test was used for categorical data. The odds ratios of the antibiotic-treated versus naive groups were calculated. All statistical analyses were performed using MedCalc Statistical Software version 18 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2018).

**Results**

**Clinical characteristics of *C. difficile tcdB* positivity and *tcdB* negativity**

The overall positivity of *C. difficile tcdB*, as determined by mPCR, was 10.1% (97/960). Patients with positive results were younger (median age, 1.6 years) than those with negative results (median age, 3.8 years) (*P* <0.01) (Table 1).

| tcdB positive (N = 97) | tcdB negative (N = 863) | *P*  |
|-----------------------|-------------------------|------|
| Age, median (95% CI)* | 1.6 (1.4–2.2)           | 3.8 (3.3–4.5) | <0.01 |
| Age group (N)         |                         |      |
| 0 (219)               |                         |      |
| Inpatient             | 12                      | 140  | 0.09 |
| Outpatient            | 11                      | 56   |      |
| Subtotal              | 23                      | 196  |      |
| 1 (153)               |                         |      |
| Inpatient             | 18                      | 95   | 0.16 |
| Outpatient            | 11                      | 29   |      |
| Subtotal              | 29                      | 124  |      |
| 2–6 (265)             |                         |      |
| Inpatient             | 11                      | 204  | <0.01|
| Outpatient            | 15                      | 61   |      |
| Subtotal              | 26                      | 239  |      |
| 7–12 (171)            |                         |      |
| Inpatient             | 7                       | 137  | 0.42 |
| Outpatient            | 3                       | 34   |      |
| Subtotal              | 10                      | 161  |      |
| 13–18 (152)           |                         |      |
| Inpatient             | 9                       | 125  | 0.36 |
| Outpatient            | 0                       | 27   |      |
| Subtotal              | 9                       | 143  |      |
| Total (960)           |                         |      |
| Inpatient             | 57                      | 674  | <0.01|
| Outpatient            | 40                      | 189  |      |
| Subtotal              | 97                      | 863  |      |
| Sex                   |                         |      |
| Male                  | 54                      | 502  | 0.64 |
| Female                | 43                      | 361  |      |
| Length of stay at testing, median (95% CI) | 5 (3.6–6.0) | 4 (4.0–5.0) | 0.807 |
| 30-day mortality      | 2                       | 10   | 0.346|
| Other gastrointestinal pathogens | Detected | 30 | 295 | 0.52 |
|                       | Not detected            | 67   | 568  |      |

* Confidence interval (CI)
No tcdB was detected in neonates (0/13). They were admitted to the neonatal intensive care unit (NICU) and administered antibiotics. Their mean length of stay was 5.0 days from the day of testing. No other diarrheal pathogens were detected in these neonates. While the youngest tcdB-positive infant was a 4-month-old, the tcdB positivity rate among infants aged 1 month to 1 year was 11.2% (23/206).

The tcdB positivity peaked at 1 year of age (29/153, 19.0%) and was inversely correlated with age. In children aged 2–6 years, the positivity rate dropped to 9.8%, and this incidence decreased in the group aged 7–12 years (5.8%) and 13–18 years (5.9%) (Fig. 1). The tcdB positivity rates were higher in outpatients than in inpatients, except in the 13–18 years group (P < 0.001).

Among inpatients, the difference in hospital length of stay between tcdB positivity and tcdB negativity was not statistically significant. Sex and 30-day mortality were not related to tcdB positivity. None of the underlying diseases were related to tcdB positivity. We categorized the underlying diseases into eight groups, and none of the odds ratios in each group reached statistical significance (data not shown).

Presence of concomitant gastrointestinal pathogens
Other gastrointestinal pathogens were detected in the stool samples from 325 patients (33.8%) using mPCR. Clostridium perfringens 32.6%, norovirus 20.9%, Campylobacter spp. 14.5%, and Salmonella spp. 10.2% were detected. Among them, 30 (9.2%) had C. difficile and other pathogens simultaneously. In 635 patients, no proven etiology of diarrhea was detected. Among them, 67 patients (9.0%) were tcdB-positive. Altogether, the presence of concomitant gastrointestinal pathogens did not affect the tcdB positivity rate (P = 0.52).

Antibiotic exposure
Antibiotic exposure did not increase tcdB positivity. The odds ratio of antibiotics in the antibiotic-treated group (N = 419) compared to that in the antibiotic-naïve group (N = 419) was 0.44 (95% confidence interval–CI: 0.28–0.67; P < 0.001). Interestingly, when we stratified the groups by age, the tcdB positivity was inversely proportional to antibiotic exposure in those under 7 years of age. The odds ratios of the groups over 7 years of age were not statistically significant (Table 2).

Diagnosis and treatment of C. difficile infection
A review of the electronic medical records revealed that a total of 22 patients (22/960, 2.3%) were clinically diagnosed with CDI and treated with metronidazole or oral vancomycin, but nine had no proven existence of C. difficile tcdB (data not shown).

Discussion
In neonates, C. difficile frequently colonizes the gastrointestinal tract without causing disease since colonization rates are reportedly 25–36% at 1 month of age [7]. Al-Jumaili et al. [10] found that the isolation rate of toxigenic C. difficile increased progressively with infant age, from 7% at birth to 100% by 26–35 days. Unlike previous reports, we did not find any toxigenic C. difficile in newborns and infants under 4 months of age. In this study, antibiotics were administered to all 13 patients in the NICU and 74% of patients under 4 months of age. In neonates, antibiotic administration has been reported to delay C. difficile colonization for at least 2 months [11]. This may explain why neither neonates nor infants of up to 3 months of age had detectable C. difficile in this study. The odds ratio, which was statistically significant in age group 0, including neonates, indicated that antibiotic usage does indeed delay C. difficile colonization (Table 2).

Larson et al. [12] surveyed three postnatal wards and reported a positivity rate of 2–52%, and their difference was statistically significant. They also found epidemiological clusters in ward environments. They suspected a nosocomial spreading, which caused the high prevalence in previous studies. Hospitals systematically develop many infection control measures, such as hand hygiene and standard precautions, which may result in a lower

Table 2 Odds ratio of antibiotics exposed group compared to antibiotics naïve group stratified by age

| Age (years) | Odds ratio | 95% CI      | P value |
|------------|------------|-------------|---------|
| 0          | 0.24       | 0.08–0.66   | <0.01   |
| 1          | 0.35       | 0.14–0.79   | 0.01    |
| 2–6        | 0.38       | 0.17–0.87   | 0.02    |
| 7–12       | 1.35       | 0.34–5.41   | 0.67    |
| 13–18      | 1.23       | 0.32–4.78   | 0.76    |
| Total      | 0.44       | 0.28–0.68   | <0.01   |

*Confidence interval (CI)
acquisition rate in neonates. Rousseau et al. [13] classified the acquisition period into the neonatal phase (early) and infant stage (4–6 months, late). Our youngest toxigenic C. difficile tcdB-positive infant was 4 months old; therefore, the subject would have been included in the "late acquisition" group in Rousseau’s study. Late acquisition was reportedly caused by modifications in the gut microbiota composition during a variable food trial.

The high colonization rate of C. difficile in infants could result from the commensal microbiota in the pre-weaning period, dominated by Bifidobacterium spp. and Lactobacillus spp., which are more permissive to colonization [14]. After solid food intake, the microbiota is similar to that of adults, dominated by Bacteroidetes and Firmicutes spp. According to a longitudinal observation of the gut microbiome analyzed by 16 S rRNA gene sequencing from an infant, the introduction of solid food at around 4 months resulted in a huge change in the microbiome and the diversity of intestinal microbiota was related to C. difficile disappearance [14]. During the observation period, C. difficile counts varied with fluctuations of more than 10^5 and eventually disappeared at 12 months. This may explain our first detection of C. difficile tcdB in a 4-month-old infant.

We observed that antibiotic usage within 30 days did not increase the positivity rate of C. difficile (Table 1). The odds ratios of the age groups 1, 2–6, and total indicated that antibiotic usage is inversely related to the tcdB positivity rate. Antibiotic use is a major risk factor for adult CDI, and research by Donata and Myers conducted in 1980 using cell culture neutralization assay (CCNA) showed that C. difficile toxin could be found in 85% of infants after 14 days of exposure to antibiotics even when the toxin was not detected during antibiotic therapy [15]. However, in our study, only 5% (3/53) were positive for C. difficile tcdB 14 days after antibiotic therapy (data not shown). Similar to our results, in a study reported in 2012 using toxigenic C. difficile culture method, antibiotic exposure prior to C. difficile detection did not cause a difference between positive patients and the overall population [13]. Although the method used in this study showed higher sensitivity than cytotoxic neutralization analysis (CCNA), the positive rate was lower. In a study using CCNA [15], vaginal delivery and breastfeeding were related to high positive rates, with differences in environmental factors thought to be the cause.

Considering how toxigenic C. difficile is acquired in these age groups, our study suggests that multiple factors beyond antibiotic usage might affect the positivity rate. Our study was based on a molecular method using fresh stool specimens to detect the C. difficile tcdB gene. Molecular testing, which uses cell culture with frozen stool samples, has a higher sensitivity than other methods. Although non-toxigenic C. difficile was not included in this study, detecting toxic C. difficile is important in clinical settings. Although molecular testing alone is too sensitive and not specific for diagnosing CDI [8], it is an appropriate test to estimate the presence of low concentrations, not infection status by C. difficile overgrowth, and production of abundant toxin.

In addition, C. difficile tcdB was detected in 10.1% of patients with diarrhea in the population under study (0–18 years of age). In a previous study, C. difficile was detected in culture samples of 7.0% of patients with diarrhea and 14.8% of patients without diarrhea between 2 weeks and 16 years of age. Therefore, the C. difficile isolation rate in patients without diarrhea was more than 50% higher than that in patients with diarrhea among outpatients [16]. Another study showed no correlation between diarrhea and C. difficile colonization rates in infants [17]. Further, a group aged over 8 years had an infection rate of approximately 5%, similar to that of healthy adults [5]. Among children under 15 years of age, Kim et al. [18] reported that 15.6% of the group with diarrhea and 6.7% of the control group had C. difficile toxin through cytotoxicity neutralization assay, indicating a higher positivity rate in diarrhea patients. In the group with diarrhea, the possibility of C. difficile infection should be considered for some positive patients.

In our results, the clinical characteristics of the tcdB-positive group were different from those of adult CDI. Patients in the C. difficile tcdB-positive group were younger than those in the negative group. tcdB-positivity was found more in outpatients than in inpatients, and length of stay was shorter in this group than in the tcdB negative group. Underlying diseases such as neoplasm, hematologic, respiratory, genitourinary disorder, and inflammatory bowel disease were not statistically related to tcdB positivity, contrary to adult CDI.

The pediatric patients included in this study were not entirely healthy since they had diarrhea that required hospital visits, during which stool samples were collected and tested for the presence of diarrhea-causing pathogens. Therefore, tcdB positivity in this study included both patients with CDI and carriers with non-CDI diarrhea etiology. A limitation of our study is that not all tcdB positivity implies colonization. In addition, this study is a retrospective study; there is a possibility that the records were inaccurate, and some data might have been omitted.

In our study, 22 patients were clinically diagnosed with CDI and treated with metronidazole or vancomycin, yet nine of them had no proven existence of C. difficile tcdB (data not shown). Moreover, 30.9% (30/97) of C. difficile tcdB-positive patients showed positive gastrointestinal pathogens simultaneously. This is in accordance with another study which reported a simultaneous positive
rate of > 50% with *C. difficile* [19]. We cannot define the remaining 70% as CDI because we could not exclude all other etiologies.

We noticed that *C. difficile* tcdB positivity was not affected by concomitant gastrointestinal pathogens. This result suggests that most *C. difficile* tcdB-positive cases are more likely to be colonization and not CDI. The clinical factors known as risk factors for CDI, such as underlying disease, antibiotic exposure, and hospital administration, did not increase the CDI positivity rate in this study. CDI cases were certainly included, but the rate did not appear to be substantial. Therefore, we may cautiously draw a sketch of pediatric CD colonization with this positivity rate rather than CDI.

**Conclusions**

*Clostridiodes difficile* is thought to be a hospital-associated infectious pathogen. The acquisition in the community seems to have prevailed due to improvements in individual hygiene levels and hospital infection control, at least in the pediatric population. This study demonstrated lower *C. difficile* positivity in the pediatric population than previously reported. Although toxigenic *C. difficile* infection is neither an important nor a common cause of pediatric diarrhea, children can spread it to adults at risk of developing CDI. Therefore, children can act as hidden reservoirs for pathogenic strains in the community. Monitoring of toxigenic *C. difficile* positivity in the pediatric population should be approached as an infection control measure, as well as individual diagnosis.

In stool samples of patients with diarrhea aged 0–18 years, *C. difficile* toxin B positivity by gastrointestinal pathogen mPCR was 10.1%. The presence of concomitant gastrointestinal pathogens was not associated with toxigenic *C. difficile* positivity; therefore, it is difficult to determine whether *C. difficile* is the cause of diarrhea in the pediatric population. The risk of transmission of CDI along with the difficulty of diagnosis should be noted.

**Abbreviations**

CDI: *Clostridiodes difficile* infection; mPCR: multiplex PCR; NICU: neonatal intensive care unit.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

JB and HK made contributions to the conception and design of the work. JB, DY, and HK made contributions to the acquisition and analysis of the data. JB and HK wrote the manuscript. JB, DY, and HK revised the manuscript. All authors have accepted their responsibility for the entire content of this manuscript and have approved its submission. All authors read and approved the final manuscript.

**Funding**

This work was supported by the National Research Foundation of Korea (NRF-2020R1F1A1066895). The funding organization had no role in the study design, the collection, analysis, and interpretation of data, and manuscript writing.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request and consultation with the IRB.

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the Institutional Review Board of Severance Hospital (2018-0281-001). The need for informed consent from participants (a parent or guardian for participants under 16 years old) was waived. The data used in this study was anonymised before its use.

** Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Laboratory Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, South Korea. 2. Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Severance Hospital, Yonsei University School of Medicine, Seoul, South Korea. 3. Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Severance Hospital, Yonsei University School of Medicine, Yongin, Gyeonggi-do, South Korea.

Received: 14 October 2021 Accepted: 29 January 2022

Published online: 05 February 2022

**References**

1. Schutze GE, Willoughby RE. *Clostridium difficile* infection in infants and children. Pediatrics. 2013;131(1):196–200.

2. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of *Clostridium difficile* disease infection in the United States. N Engl J Med. 2015;372(9):825–34.

3. Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among *Clostridium difficile* clinical isolates. J Clin Microbiol. 2002;40(9):3470–5.

4. Chitnis AS, Holzbauer SM, Bellflower RM, Winston LG, Bamber WM, Lyons C, et al. Epidemiology of community-associated *Clostridium difficile* infection, 2009 through 2011. JAMA Intern Med. 2013;173(14):1359–67.

5. Miyajima F, Roberts P, Swale A, Price V, Jones M, Horan M, et al. Characterisation and carriage ratio of *Clostridium difficile* strains isolated from a community-dwelling elderly population in the United Kingdom. PLoS One. 2011;6(8):e22804.

6. Jangi S, Lamont JT. Asymptomatic colonization by *Clostridium difficile* in infants: implications for disease in later life. J Pediatr Gastroenterol Nutr. 2010;51(1):2–7.

7. Lees E, Miyajima F, Pirmohamed M, Carrol E. The role of *Clostridium difficile* in the paediatric and neonatal gut—a narrative review. Eur J Clin Microbiol Infect Dis. 2016;35(7):1047–57.

8. McDonald LC, Gerdg DN, Johnson S, Bakken JS, Caroll KC, Coffin SE, et al. Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–48.

9. Sawyer SM, McNeil R, Francis KL, Matskarofski JZ, Patton GC, Bhutta ZA, et al. The age of paediatrics. Lancet Child Adolesc Health. 2019;3(11):822–30.
10. Al-Jumaili I, Shibley M, Lishman A, Record C. Incidence and origin of *Clostridium difficile* in neonates. J Clin Microbiol. 1984;19(1):77–8.
11. Holton A, Hall M, Lowes J. Antibiotic exposure delays intestinal colonization by *Clostridium difficile* in the newborn. J Antimicrob Chemother. 1989;24(5):811–7.
12. Larson H, Barclay F, Honour P, Hill I. Epidemiology of *Clostridium difficile* in infants. J Infect Dis. 1982;146(6):727–33.
13. Rousseau C, Poulard I, De Pontual L, Maherault A-C, Le Monnier A, Collignon A. *Clostridium difficile* carriage in healthy infants in the community: a potential reservoir for pathogenic strains. Clin Infect Dis. 2012;55(9):1209–15.
14. Davis MY, Zhang H, Brannan LE, Carman RJ, Boone JH. Rapid change of fecal microbiome and disappearance of *Clostridium difficile* in a colonized infant after transition from breast milk to cow milk. Microbiome. 2016;4:53.
15. Donta ST, Myers MG. *Clostridium difficile* toxin in asymptomatic neonates. J Pediatr. 1982;100(3):431–4.
16. Boening DA, Fleisher GR, Campos JM, Hulikower CW, Quinlan RW. *Clostridium difficile* in a pediatric outpatient population. Pediatr Infect Dis. 1982;15(5):336–8.
17. Holst E, Helin I, Mårkd P-A. Recovery of *Clostridium difficile* from children. Scand J Infect Dis. 1981;13(1):41–5.
18. Kim K, Suh I-S, Kim JM, Kim CW, Cho Y-J. Etiology of childhood diarrhea in Korea. J Clin Microbiol. 1989;27(6):1192–6.
19. Valentin D, Vittucci A, Grandin A, Tozzi A, Russo C, Onori M, et al. Coinfection in acute gastroenteritis predicts a more severe clinical course in children. Eur J Clin Microbiol Infect Dis. 2013;32(7):909–15.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.